Rasmussen Carol A, Kaufman Paul L
Department of Ophthalmology & Visual Sciences, School of Medicine & Public Health, University of Wisconsin-Madison, Madison, WI, USA..
Department of Ophthalmology & Visual Sciences, School of Medicine & Public Health, University of Wisconsin-Madison, Madison, WI, USA.
Can J Ophthalmol. 2014 Dec;49(6):534-43. doi: 10.1016/j.jcjo.2014.08.007.
Glaucoma is a complex, life-long disease that requires an individualized, multifaceted approach to treatment. Most patients will be started on topical ocular hypotensive eyedrop therapy, and over time multiple classes of drugs will be needed to control their intraocular pressure. The search for drugs with novel mechanisms of action, to treat those who do not achieve adequate intraocular pressure control with, or become refractory to, current therapeutics, is ongoing, as is the search for more efficient, targeted drug delivery methods. Gene-transfer and stem-cell applications for glaucoma therapeutics are moving forward. Advances in imaging technologies improve our understanding of glaucoma pathophysiology and enable more refined patient evaluation and monitoring, improving patient outcomes.
青光眼是一种复杂的终身疾病，需要采用个性化、多方面的治疗方法。大多数患者将开始使用局部降眼压眼药水治疗，随着时间的推移，需要多种药物来控制眼压。目前正在寻找具有新作用机制的药物，以治疗那些眼压控制不佳或对现有治疗产生耐药性的患者，同时也在寻找更有效、靶向性更强的药物递送方法。青光眼治疗的基因转移和干细胞应用也在不断推进。成像技术的进步加深了我们对青光眼病理生理学的理解，使患者评估和监测更加精确，从而改善患者的治疗效果。
